The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence

Author(s): Samuel D. Banister, Michael Kassiou.

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 7 , 2012

Become EABM
Become Reviewer

Abstract:

Since their proposal in 1976, sigma (σ) receptors have been increasingly implicated in the pathophysiology of virtually all major central nervous system (CNS) disorders, including anxiety, depression, schizophrenia, and drug addiction. Due to their involvement in motor function and higher cognitive function,σ receptors have also been implicated in movement disorders (such as Parkinson's disease) and memory deficits (including Alzheimer's disease). In most cases the precise mechanism(s) linking σ receptors to CNS disease are unknown or yet to be fully elucidated. However, many σ ligands have shown promise in pharmacological studies and animal models of the aforementioned diseases, and some have entered clinical trials. This review will assess the validity of σ receptors as a target for various CNS diseases based on evidence from animal models of human diseases, preclinical studies in humans, and full clinical trials.

Keywords: Sigma receptor, central nervous system, schizophrenia, anxiety, depression, Alzheimer's disease, addiction, pain, clinical trials, tumor cells

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 7
Year: 2012
Page: [884 - 901]
Pages: 18
DOI: 10.2174/138161212799436539

Article Metrics

PDF: 50